Navigation Links
GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
Date:4/1/2009

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information please visit us.gsk.com

BOXED WARNING and Additional Important Safety Information for TYKERB

Hepatotoxicity - TYKERB has been associated with hepatotoxicity. Hepatotoxicity (ALT or AST >3 times the upper limit of normal and total bilirubin >1.5 times the upper limit of normal) has been observed in clinical trials (<1% of patients) and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after initiation of treatment. Liver function tests should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. If changes in liver function are severe, therapy with TYKERB should be discontinued and patients should not be re-treated with TYKERB.

Decreased Left Ventricular Ejection Fraction - TYKERB has been reported to decrease LVEF. Caution should be taken if TYKERB is to be administered to patients with preexisting cardiac conditions, including uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure. Confirm normal LVEF before starting TYKERB, and continue evaluations during treatment.

Patients with Severe Hepatic Impairment - If TYKERB is to be administered to patients with severe hepatic impairment, dose reduction should be considered.

Diarrhea - Diarrhea, including severe diarrhea, has been reported during treatment with TYKERB and was the most common adverse reaction resulting in discontinuation of TYKERB therapy. Proactive management of diarrhea w
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
2. Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
3. Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine)
4. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
5. STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter
6. TriServ Alliance Submits Final Bid for TRICARE South Region Contract
7. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
8. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
9. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
10. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
11. TriServ Alliance Submits Bid for TRICARE South Region Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... August 01, 2014 The American ... Gregg Harper (R-MS), and Peter Welch (D-VT), for ... Medicare Telehealth Parity Act of 2014, which improves ... this effort to improve healthcare access and affordability ... officer of ATA. "These cost-saving provisions are critical ...
(Date:8/1/2014)... On Monday, June 30th, the Quirk ... in San Francisco, CA. Now in its fourth year, ... Union Square hotel. , “We are excited about returning ... with ACA compliance issues,” Quirk Healthcare Foundation Executive Director, ... attendees guidance with NextGen implementation and use, electronic records ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although many parents ... many overlook a common choking hazard: food. Such ... wheeze and cough after eating a handful of nuts. ... not obvious if the coughing was related to his illness ... wasn,t a cold. A cashew had become lodged in his ...
(Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
(Date:8/1/2014)... Oxford Gene Technology (OGT) is ... products include CytoSure heamatological cancer +SNP Array, CytoSure ... UPD array, CytoSure ISCA sample tracking spike-ins and ... such as targeted sequencing services, SureSeq Solid Tumour ... expression analysis, cytosure services and aCGH for CNV ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... September 9, 2010 Amyloid beta (Αβ) proteins, ... transport of vital cargoes inside brain cells. Scientists at ... that reducing the level of another protein, tau, can ... in the brain are connected to many other neurons ...
... of the Hastings Center Report ... to legalize physician-assistance in dying, either do not participate ... assistance. Both legal and moral reasons are identified. ... for assuring that physician-assisted death is carried out responsibly, ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Sept. ... quick MRI scan could tell doctors if a child,s brain ... mental problems are developing. Researchers say the strategy could ... the age-old growth charts that tell pediatricians if kids are ...
... Amsterdam, The Netherlands, September 2010 More than ... all over the world met at the 23rd Congress of ... 1 September 2010 in Amsterdam. The ECNP Congress is ... this year included 46 sessions presented by ...
... Virginia Commonwealth University Medical Center is the lead institution in ... heart patients to recuperate, rehabilitate and wait in the comfort ... for transplant. , The VCU Pauley Heart Center is one ... mechanical driver that can power patients, artificial hearts and enable ...
... the world,s population is infected with Mycobacterium tuberculosis (MTB), ... death world-wide. A new discovery, led by a team ... Medicine, offers hope for new approaches to the prevention ... novel mechanism that may contribute to immune recognition of ...
Cached Medicine News:Health News:Strategy discovered to prevent Alzheimer's-associated traffic jams in the brain 2Health News:Study finds most Oregon hospices do not fully participate in the Death with Dignity Act 2Health News:Brain Scans Could Spot Developmental Problems in Kids 2Health News:23rd ECNP Congress: Europe's largest scientific meeting on mental health 2Health News:VCU Medical Center leads study of first US portable driver for powering the total artificial heart 2Health News:New dual recognition mechanism discovered in tuberculosis 2Health News:New dual recognition mechanism discovered in tuberculosis 3
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Amar Singh , Chief Business Officer and Executive Vice ... causes on July 30. "Sorrento is deeply saddened ... colleague. Our immediate thoughts go to Amar,s family and friends," ... Executive Officer. Mr. Singh joined Sorrento in ...
(Date:7/31/2014)... July 31, 2014  ResMed Inc. (NYSE: RMD ... the fiscal year ended June 30, 2014.  Revenue for the ... June 30, 2013 (a 1 percent decrease on a constant ... 20 percent compared to the quarter ended June 30, 2013. ... increase of 22 percent compared to the quarter ended June ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... Inc., developer of the VerifyNow® System, the first rapid ... multiple antiplatelet agents, announced today that the VerifyNow P2Y12 ... identifying patients with high residual platelet reactivity (also termed ... at greater risk for future cardiovascular events. ...
... the second year in a row, A dvertising ... Communication Group ( www.eveo.com ) as the #1 Independent Digital Healthcare ... annual A d A ... the first time. (Photo:   http://photos.prnewswire.com/prnh/20110516/SF03150 ) ...
Cached Medicine Technology:New CE Marked Prognostic Claim for the VerifyNow P2Y12 Test 2New CE Marked Prognostic Claim for the VerifyNow P2Y12 Test 3Eveo Ranked #1 Independent Digital Healthcare Agency in U.S. 2nd Year in a Row 2
... DeepLight Glaucoma Treatment System will ... effective glaucoma treatments through the ... Micro-Shunt (GMS) and DeepLight 790 ... use the eye's natural pressure ...
The Verity ADx pacemaker family, which includes the world's longest lasting single- and dual-chamber pacemakers, provides clinicians with a variety of feature options and header configurations to mee...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... Identity ADx pacemaker family, which ... pacemaker, provides clinicians with the ... including the revolutionary AF Suppression™ ... U.S. commercially approved algorithm designed ...
Medicine Products: